



image

\$ AF
TCS

Attorney Docket No. 60019610-0235

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:) Group Art Unit: 1623
Daniela SALVEMINI) Examiner: Kathleen Kohler Fonda
Application No. 09/997,974)
Filed: November 30, 2001)
For: SODm Therapy for Prevention and/or)
Treatment of Inflammatory Disease)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
ATTENTION: GROUP DIRECTOR

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT AFTER
MAILING DATE OF FINAL ACTION OR NOTICE OF ALLOWANCE
BUT BEFORE PAYMENT OF ISSUE FEE (37 C.F.R. § 1.97(d))**

**TIME OF TRANSMITTAL OF ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

Transmittal of Information Disclosure Statement
Page 2

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Pursuant to 37 C.F.R. § 1.97(e)(2), no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement.

Applicant hereby petitions for the consideration of the accompanying information disclosure statement. 37 C.F.R. § 1.97(d)(2).

Applicant submits a credit card payment form in the amount of \$180.00 for the petition fee set forth in 37 C.F.R. § 1.17(p).

The Commissioner is hereby authorized to credit overpayments or to charge any deficiency in a required fee to Deposit Account No. 19-3140. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Dated: 3/24/04

By:

KW. Buckley

Kevin W. Buckley, Reg. No. 45,901
Customer No. 26263
(314) 259-5817



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control number.


Information Disclosure Statement by Applicant <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/997,974
				Filing Date	November 30, 2001
				First Named Inventor	Daniela Salvemini
				Group Art Unit	1623
				Examiner Name	Kathleen Kohler Fonda
Sheet	1	of	3	Attorney Docket Number	60019610-0235

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	59	US-3,903,297	09-02-1975	Robert	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box TM +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>			Complete if Known	
			Application Number	09/997,974
			Filing Date	November 30, 2001
			First Named Inventor	Daniela Salvemini
			Group Art Unit	1623
			Examiner Name	Kathleen Kohler Fonda
			Attorney Docket No.	60019610-0235
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	60	MARZULLO et al., "Opiate Receptor Function May Be Modulated Through an Oxidation-Reduction Mechanism," <i>Science</i> , 1980, pp. 1171-1173, Vol. 208.		
	61	CADET, "Free Radical Mechanisms in the Central Nervous System: An Overview," <i>Int. J. Neurosci.</i> , 1988, pp. 13-18, Vol. 40.		
	62	MARSHALL, "Solid Oral Dosage Forms," Chapter 10 of <i>Modern Pharmaceutics</i> , 1979, pp. 359-427, Vol. 7.		
	63	HARGREAVES et al., "Basic Section - A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia," <i>Pain</i> , 1988, pp. 77-88, Vol. 32.		
	64	TALLARIDA et al., "Statistical Analysis of Drug-Drug and Site-Site Interactions with Osobograms," <i>Life Sciences</i> , 1987, pp. 947-961, Vol. 45.		
	65	OSSIPOV et al., "An Isobolographic Analysis of the Antinociceptive Effect of Systemically and Intrathecally Administered Combinations of Clonidine and Opiates," <i>J. Pharmacol. Exp. Ther.</i> , 1990, pp. 1107-1116, Vol. 255.		
	66	PORRECA et al., "Short Communication - Modulation of Morphine Antinociception by Peripheral [Leu ⁵]enkephalin: A Synergistic Interaction," <i>Euro. J. Pharm.</i> , 1990, pp. 463-468, Vol. 179.		
	67	HUNSKAAR et al., "The Formalin Test in Mice: Dissociation Between Inflammatory and Non-Inflammatory Pain," <i>Pain</i> , 1987, pp. 103-114, Vol. 30.		
	68	OSSIPOV et al., "Characterization of Supraspinal Antinociceptive Actions of Opioid Delta Agonists in the Rat," <i>Pain</i> , 1995, pp. 287-293, Vol. 62.		
	69	OSSIPOV et al., "The Increase in Morphine Antinociceptive Potency Produced by Carrageenan-Induced Hindpaw Inflammation is Blocked by Naltrindole, a Selective δ -Opioid Antagonist," <i>Neurosci. Lett.</i> , 1995, p. 173-176, Vol. 184.		
	70	OSSIPOV et al., "Inhibition by Spinal Morphine of the Tail-Flick Response is Attenuated in Rats with Nerve Ligation Injury," <i>Neurosci. Lett.</i> , 1995, pp. 83-86, Vol. 199.		
	71	OSSIPOV et al., "The Loss of Antinociceptive Efficacy of Spinal Morphine in Rats with Nerve Ligation Injury is Prevented by Reducing Spinal Afferent Drive," <i>Neurosci. Lett.</i> , 1995, pp. 87-90, Vol. 199.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Institute for form 1449B/PTO			<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	09/997,974
<i>(use as many sheets as necessary)</i>			Filing Date	November 30, 2001
			First Named Inventor	Daniela Salvemini
			Group Art Unit	1623
			Examiner Name	Kathleen Kohler Fonda
Sheet	3	of 3	Attorney Docket No.	60019610-0235
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	72	KOCHER et al., "Basic Section - The Effect of Carrageenan-Induced Inflammation on the Sensitivity of Unmyelinated Skin Nociceptors in the Rat," Pain, 1987, pp. 363-373, Vol. 29.		
	73	KOCHER, "A Proposal for a Generally Application <i>de minimis</i> Dose," Health Physics, 1987, pp. 117-121, Vol. 53.		
	74	KOCHER et al., "Analysis of α -Smooth-Muscle Actin mRNA Expression in Rat Aortic Smooth-Muscle Cells Using Specific cDNA Probe," Differentiation, 1987, pp. 201-209, Vol. 34.		
	75	KOCHER et al., "Electron Dose-Rate Conversion Factors for External Exposure of the Skin From Uniformly Deposited Activity on the Body Surface," Health Physics, 1987, pp. 135-141, Vol. 53.		
	76	KOCHER, "Evaluation of a Terrestrial Food-Chain Model Using Natural Analogs," Health Physics, 1987, pp. 79-82, Vol. 52.		
Examiner Signature			Date Considered	

23135501\W-1